Tag: Biotech and Pharma

Sarepta Therapeutics Inc.’s (SRPT) gene therapy received expanded US approval to include more children with a deadly muscle disease, expanding the market for a controversial treatment that still hasn’t proved its benefit in clinical trials.

Johnson & Johnson has agreed to pay $700 million to settle an investigation by 42 U.S. states and Washington, D.C. into its marketing of baby powder and other talc-based products blamed for allegedly causing cancer.

A panel of independent advisors to the Food and Drug Administration on Monday recommended Eli Lilly’s Alzheimer’s drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year.

Shares of GSK dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer, to go forward, in a blow for the British drugmaker.

Merck & Co. Inc. announced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused biotechnology company, in a deal that could be valued at up to $3 billion.

Αύξηση κατά 15,9% παρουσιάζουν τα συνολικά κέρδη προ φόρων, τόκων και αποσβέσεων (EBITDA) του Ομίλου της Lavipharm για το Α’ τρίμηνο του 2024, τα οποία διαμορφώθηκαν σε €2,85 εκατ. έναντι €2,46 εκατ. κατά το αντίστοιχο διάστημα του προηγούμενου έτους, σύμφωνα με σχετική ανακοίνωση.

Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023.

Merck KGaA on Wednesday reported better-than-expected adjusted earnings, helped by strong demand for its pharmaceuticals and amid currency-adjusted sales growth in semiconductor materials.

Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year’s annual ‘Choose France’ business summit.

Novavax on Friday said it has signed a multibillion-dollar deal with French drugmaker Sanofi to co-commercialize the company’s Covid vaccine starting next year and develop combination shots targeting the coronavirus and the flu, among other efforts. 

AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a “surplus of available updated vaccines” since the pandemic.

Novo Nordisk, which became the most valuable company in Europe last year due to the blockbuster success of its weight loss drugs, on Thursday beat first-quarter profit expectations as demand for those medications boomed.

Pfizer on Wednesday reported first-quarter revenue that beat expectations and hiked its full-year profit outlook, benefitting from its broad cost-cutting program and strong sales of its non-Covid products.

Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street’s expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound.

 Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of strong sales for its blockbuster cancer drug Keytruda, sending the company’s shares up more than 2% before the bell.

Στις θετικές προοπτικές που διανοίγονται τόσο για φέτος, όσο και για τα επόμενα χρόνια, αναφέρθηκε η διοίκηση της Lavipharm-1,05% στο πλαίσιο της χθεσινής παρουσίασης της εισηγμένης εταιρείας στην Ένωση Θεσμικών Επενδυτών.

Biogen reported first-quarter profit that topped estimates as the company’s cost-cutting efforts took hold and sales of its closely watched Alzheimer’s drug, Leqembi, came in higher than expected.

Shares of Swiss drugmaker Novartis climbed as much as 4.8% in early deals on Tuesday, after the company raised its full-year guidance following better-than-expected first-quarter results.

 Drugmaker Bristol Myers Squibb said it has signed a $380 million deal with contract manufacturer Cellares to manufacture its CAR-T cell therapies in the United States, EU and Japan.

Shares of Cardinal Health were falling after the drug maker said it won’t be renewing a distribution contract with pharmacy benefits manager OptumRx.